PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.87%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 0.02%. Joel Greenblatt would verify if operating margins keep pace with this top-line surge.
12.17%
Positive gross profit growth while Medical - Pharmaceuticals median is negative. Peter Lynch would see a notable competitive edge in cost or pricing.
54.90%
EBIT growth exceeding 1.5x Medical - Pharmaceuticals median of 11.71%. Joel Greenblatt would examine whether a unique competitive edge supports this outperformance.
49.18%
Operating income growth exceeding 1.5x Medical - Pharmaceuticals median of 5.22%. Joel Greenblatt would see if unique processes drive exceptional profitability.
14.74%
Net income growth near Medical - Pharmaceuticals median of 14.74%. Charlie Munger would see common industry factors at play.
14.74%
EPS growth near Medical - Pharmaceuticals median of 14.89%. Charlie Munger might conclude it’s in line with industry norms.
14.74%
Diluted EPS growth near Medical - Pharmaceuticals median of 14.89%. Charlie Munger would expect typical industry-level share usage and profit trends.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.28%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.29%. Seth Klarman would see an advantage if others are still diluting.
-100.00%
Dividend cuts while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others maintain or grow payouts, highlighting a relative weakness.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
149.77%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 56.32%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
59.05%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 19.46%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
38.14%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 17.06%. Joel Greenblatt might see a short-term competitive advantage at play.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
199.81%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 46.32% over a decade. Joel Greenblatt might see a standout compounder of earnings.
61.16%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 29.99%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
30.34%
3Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 14.92%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
318.66%
Equity/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 42.71% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
81.97%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 12.31%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
35.33%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 6.97%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.30%
AR growth of 3.30% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
0.78%
Inventory growth far above Medical - Pharmaceuticals median. Jim Chanos suspects major issues in demand forecasting or potential obsolescence risk.
1.69%
We expand assets while Medical - Pharmaceuticals is negative. Peter Lynch sees a possible advantage if expansions align with profitable markets or a recovering cycle.
2.49%
Positive BV/share change while Medical - Pharmaceuticals median is negative. Peter Lynch finds a strong advantage vs. peers failing to expand equity.
-21.26%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
5.14%
Our SG&A slightly up while Medical - Pharmaceuticals is cutting. Peter Lynch wonders if we overspend or if the median underinvests in marketing.